The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-Atherosclerosis is characterized as a chronic inflammatory condition that involves cholesterol deposition in arteries. Together with scavenger receptor B1 (SR-B1), the ATP-binding cassette transporters ABCA1 and ABCG1 are the major components of macrophage cholesterol efflux. Recent studies have shown that low-grade inflammation plays a distinct regulatory role in the expression of SR-B1 and ABCA1/ABCG1. However, the mechanisms linking low-grade inflammation and cholesterol accumulation are poorly understood. Methods and Results-Using primary bone-marrow-derived macrophages, we demonstrate that subclinical low-dose lipopolysaccharide potently reduces the expression of SR-B1 and ABCA1/ABCG1, as well as cholesterol efflux from macrophages through interleukin-1 receptor-associated kinase 1 and Toll-interacting-protein. Low-dose lipopolysaccharide downregulates the nuclear levels of retinoic acid receptor-α, leading to their reduced binding to the promoters of SR-B1 and ABCA1/ABCG1. We observe that glycogen synthase kinase 3β activation by low-dose lipopolysaccharide through interleukin-1 receptor-associated kinase 1 and Toll-interacting-protein is responsible for reduced levels of retinoic acid receptor-α, and reduced expression of SR-B1 and ABCA1/ABCG1. Interleukin-1 receptor-associated kinase M, however, counteracts the function of interleukin-1 receptor associated kinase 1. Conclusion-Collectively, our data reveal a novel intracellular network regulated by low-dose endotoxemia that disrupts cholesterol efflux from macrophages and leads to the pathogenesis of atherosclerosis. (Arterioscler Thromb Vasc Biol. 2013;33:24-33.)
A therosclerosis underlies the pathogenesis of a wide range of cardiovascular diseases. Consequently, atherosclerosis and related cardiovascular complications are among the leading causes of morbidity and mortality in the United States. [1] [2] [3] Despite significant improvements in clinical diagnosis and patient care, the incidence of atherosclerosis has been increasing in the last decade, potentially due to changing life styles. 3 Atherosclerosis-related diseases were estimated to cost >$500 billion annually in the United States. 4, 5 Recent studies indicate that low-grade endotoxemia may be one of the culprits for the pathogenesis of atherosclerosis. Both external and internal risk factors, including infections and high-fat diets, can dramatically alter the landscape of gut microbiota, increase mucosal permeability, and, as a consequence, raise the levels of circulating bacterial endotoxin lipopolysaccharide (LPS). [6] [7] [8] [9] Indeed, slightly elevated levels of blood endotoxin (<100 pg/mL) were observed in humans with chronic cardiovascular diseases, higher body mass indexes, and in aged adults with inflammatory complications. [10] [11] [12] In contrast to the effect of high-dose LPS (>10 ng/mL), which can induce major cytokine storms and septic shock, the trace amount of LPS seen in chronic subclinical endotoxemia (<100 pg/mL) does not induce acute cytokine storm. Instead, subclinical endotoxemia induces mild, yet persistent, elevation of inflammatory mediators, potentially leading to low-grade inflammation and pathogenesis of atherosclerosis. Despite significant pathological implication of low-dose endotoxemia, the molecular mechanisms responsible for the effects of lowdose endotoxin are not well understood. We reported that low-dose LPS fails to activate the classical nuclear factor κB pathway. 13 Instead, low-dose LPS preferentially induces the mild induction of proinflammatory mediators through ATF2, C/EBPδ, and mitochondria-reactive-oxygen species. 13, 14 In terms of the intracellular-signaling components, we observed that the interleukin-1 receptor-associated kinase 1 (IRAK-1) and Toll-interacting-protein (Tollip) are critically required for the effects of low-dose LPS, without compromising the effects of high-dose LPS. 13, 14 Bacterial endotoxin not only induces proinflammatory mediators, but also suppresses the expression of antiinflammatory mediators. 15, 16 Of particular relevance, scavenger receptor B1 (SR-B1) and ABCA1 are among the antiinflammatory mediators expressed by macrophages. 17, 18 These membrane transporters are essential for cholesterol export from macrophages and maintaining macrophage homeostasis. 17, 19 Together with SR-B1, ABCA1 and ABCG1 contribute to the efflux of cholesterol from macrophages and prevent the formation of foam cells. SR-B1 promotes bidirectional cholesterol exchange between cells and lipoproteins, including highdensity lipoprotein (HDL). ABCA1 facilitates cholesterol export to lipid-free apolipoprotinA-1 (ApoA-1) and generation of HDL, whereas ABCG1 acts to export cholesterol to mature HDL particles. 19 In the meantime, ABCA1 attenuates toll-like receptor-4 signaling and alleviates inflammatory response to LPS. 17 The expressions of ABCA1 and ABCG1 are controlled by nuclear receptors, including retinoic acid receptor-α (RARα). 20, 21 We and others have shown that LPS can suppress nuclear receptors and reduce retinoic-acid-induced expression of ABCA1. [22] [23] [24] [25] We also reported that several key intracellular signaling molecules, including IRAK-1, are involved in the suppression of RARα by low-dose LPS. 13 The molecular mechanisms responsible for the suppression of macrophage cholesterol export by low-dose LPS are not well studied. We reported that low-dose LPS preferentially reduces levels of nuclear receptor RARα, which is responsible for the expression of ABCA1 and ABCG1, as well as the suppression of proinflammatory mediators. 13, 23 This current study further examines the mechanisms responsible for reduced cholesterol export in macrophages treated with low-dose LPS. Using primary macrophages harvested from wild-type (WT), IRAK-1-deficient, Tollip-deficient, and IRAK-M-deficient mice, we examined the molecular pathways responsible for the reduced expression of cholesterol transporters in macrophages by low-dose LPS.
Materials and Methods
Detailed protocols are given in the online-only Data Supplement Materials and Methods.
Reagents
LPS (Escherichia coli O111:B4) was obtained from Sigma. The antibodies against RARα, glyceraldehyde 3-phosphate dehydrogenase, steroid receptor coactivator 3 (SRC3), glycogen synthase kinase 3β (GSK3β), pGSK3β-Tyr216, and β-actin were purchased from Santa Cruz Biotechnology. ABCA1, ABCG1, and SR-B1-specific antibodies were obtained from Novus Biologicals, and the pGSK3β-Ser9, LaminB antibodies were purchased from Cell Signaling. [ 3 H]cholesterol (40 Ci/mmol) was obtained from Perkin-Elmer. Mice C57BL/6 WT mice were purchased from the Jackson laboratory. IRAK-1-deficient mice were obtained from James Thomas (University of Texas Southwestern Medical School). Tollip-deficient mice were provided by Jürg Tschopp (University of Lausanne at Switzerland). IRAK-M-deficient mice were provided by Richard Flavell (Yale University School of Medicine). The WT-and GSK3βdeficient murine embryonic fibroblast cells were obtained from James Woodgett (Ontario Cancer Institute). All mice were housed and bred at Derring Hall animal facility in compliance with approved Animal Care and Use Committee protocols at Virginia Polytechnic Institute and State University. Bone-marrow-derived macrophages were isolated from the tibias and femurs of mice by flushing the bone marrow with Dulbecco's modified Eagle's medium. The cells were cultured in untreated tissue culture dishes with 50 mL Dulbecco's modified Eagle's medium containing 30% L929 cell supernatant. On the third day of culture, the cells were fed with an additional 20 mL fresh medium and cultured for another additional 3 days. Cells were harvested with phosphate-buffered saline, resuspended in Dulbecco's modified Eagle's medium supplemented with 1% fetal bovine serum, and allowed to rest overnight before further treatments.
Statistical Analysis
Statistical significance was determined using the unpaired 2-tailed Student t test. P values <0.05 were considered statistically significant. Data are expressed as mean±SD.
Results

Low-Dose LPS Decreases the Expression of SR-B1, ABCA1, and ABCG1, as well as Cholesterol Efflux to HDL and ApoA-1
We first examined the expression levels of SR-B1, ABCA1, and ABCG1 in murine bone-marrow-derived macrophages treated with a low-dose LPS (50 pg/mL). As shown in Figure 1A , the RNA levels of Sr-b1, Abca1, and Abcg1 decreased significantly in response to low-dose LPS treatment. We further examined their protein levels by Western blot analyses. As shown in Figure 1B , the protein levels of SR-B1, ABCA1, and ABCG1 were significantly reduced after low-dose LPS treatment ( Figure 1B ). To determine whether decreased expression of these molecules may translate into compromised cholesterol export in macrophages, we performed cholesterol export assay, as previously described. 23 The primary function of the membrane transporters, ABCA1 and ABCG1, involve mediating cholesterol efflux to apoA-1 and HDL, respectively, to reduce the build up of cholesterol within the cells. SR-B1 can facilitate the cholesterol export mediated by ABCA1 and ABCG1. As shown in Figure 1C , the cholesterol exports to both Apo-A1 and HDL were significantly reduced in cells treated with low-dose LPS for 18 hours. These results indicate that low-dose LPS suppresses cholesterol export from macrophages, through suppressing the expression of SR-B1, ABCA1, and ABCG1.
IRAK-1 and Tollip Are Critically Involved in the Suppression of Macrophage Cholesterol Export by Low-Dose LPS
Previous studies indicate that IRAK-1 and Tollip are preferentially involved in mediating the low-grade inflammatory effects elicited by low-dose LPS. 13, 26 Tollip is a novel adaptor molecule selectively associated with IRAK-1. 27 Therefore, we tested whether the suppressive effect of low-dose LPS on cholesterol export depends upon IRAK-1 and Tollip. As shown in Figure 2 , low-dose LPS failed to suppress cholesterol efflux activities to either ApoA-1 or HDL in IRAK-1-deficient or Tollip-deficient macrophages.
To further determine the underlying molecular mechanisms, we tested the involvement of IRAK-1 and Tollip in the expression of key cholesterol exporters, including SR-B1, ABCA1, and ABCG1. Consistent with previous reports, we observed that low-dose LPS significantly suppressed the transcript and protein expressions of these transporters in WT macrophages ( Figure 3A and 3B). In sharp contrast, low-dose LPS failed to suppress the expression of SR-B1, ABCA1, and ABCG1 in IRAK-1-deficient or Tollip-deficient macrophages ( Figure 3 ). These data indicate that IRAK-1 and Tollip are involved in the downstream effect of low-dose LPS in modulating the expression and function of macrophages cholesterol exporters.
Low-Dose LPS Suppresses RARα Through IRAK-1 and Tollip
We then examined the levels of key transcription factors responsible for the gene transcription of these cholesterol transporters. Earlier studies have shown that ABCA1 expression can be upregulated by members of the nuclear receptor family, such as RARα, liver X receptor-α, and peroxisome proliferatoractivated receptors (PPARs). 21, 23, 28 Therefore, we examined the nuclear levels of RARα and liver X receptor-α in macrophages harvested from WT, IRAK-1-deficient, and Tollipdeficient mice. As shown in Figure 4A , the nuclear levels of RARα and liver X receptor-α were significantly reduced in WT macrophages, but not in IRAK-1-deficient and Tollip deficient macrophages. Therefore, low-dose LPS-mediated suppression of nuclear RARα and liver X receptor-α levels was mediated through IRAK1 and Tollip.
The transcriptional activity of RARα relies on its ability to recruit coactivators, such as SRC. SRC3 facilitates RARdirected chromatin remodeling and favors the generation of a transcriptionally permissive environment at the responsive promoter elements. 29 Thus, we tested whether low-dose LPS may also affect the levels of SRC3. As shown in Figure 4B , the levels of SRC3 were significantly reduced in WT bone marrow derived macrophages treated with low-dose LPS. In contrast, low-dose LPS failed to alter the levels of nuclear SRC3 in either IRAK-1-deficient or Tollip-deficient macrophages.
We further carried out chromatin immunoprecipitation assays to evaluate the binding of nuclear receptors to the endogenous promoters of Sr-b1, Abca1/Abcg1 in WT, Figure 1 . Low-dose lipopolysaccharide (LPS) reduces the expression and function of cholesterol transporters. A, Wild-type (WT) bone-marrow-derived macrophage (BMDM) cells were either treated with low-dose LPS (50 pg/mL) for the indicated time periods or left untreated for 18 hours, and the expression levels of Srb1, Abca1, and Abcg1 transcripts were measured by RT-PCR assays, and standardized against Gapdh levels. Each experiment was performed in triplicate. * indicates P<0.05 compared with the untreated control samples. Error bars represent SD. B, WT BMDM cells were either untreated or treated with low-dose LPS (50 pg/mL) for 6 hours and 18 hours followed by Western blot analysis of total cell extracts (70 μg), using scavenger receptor B1 (SR-B1), ABCA1, and ABCG1-specific antibodies. Antibodies against glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were used as the internal loading control. The data are representative of at least 3 independent experiments. C, The BMDMs derived from WT mice were radiolabeled with [ 3 H]cholesterol in cell culture medium for 18 hours, and then treated with or without low-dose LPS (50 pg/mL) in the presence of apolipoprotinA-1 (apoA-1; 10 μg/mL) or HDL (50 μg protein/mL). Cellular cholesterol efflux was analyzed in liquid scintillation counting assays, and the efflux rates were calculated as described in the onlineonly Data Supplement Methods. Efflux rates were expressed as means±standard deviations from 3 independent experiments, each performed in triplicate. * indicates P<0.05 compared with the untreated control samples. IRAK-1-deficient and Tollip-deficient macrophages treated with low-dose LPS. As shown in Figure 4C , low-dose LPS treatment led to reduced binding of RARα to the promoters of Sr-b1, Abca1/Abcg1 in WT, but not in IRAK-1-deficient or Tollip-deficient macrophages. Low-dose LPS also reduced the recruitment of SRC3 to the Abca1 promoter. There was no detectable binding of SRC3 to the Abcg1 promoter, indicating that there may be distinct and gene-specific regulation of Abca1 and Abcg1.
Low-Dose LPS Suppresses the Expression of Cholesterol Exporters Through IRAK-1/ Tollip-Mediated Activation of GSK3β
GSK3β is known to cause degradation and inactivation of both RARα and SRC3. 30, 31 Thus, we tested whether low-dose LPS may suppress RARα through activation of GSK3β. A previous study indicates that low-dose LPS causes GSK3β activation in vivo. 32 GSK3β is modulated by 2 distinct phosphorylation events at Serine 9 and Tyrosine 216. Ser9 phosphorylation suppresses, whereas Tyr216 phosphorylation activates GSK3β activity. We observed that low-dose LPS preferentially induced Tyr216 phosphorylation, and suppressed Ser9 phosphorylation of GSK3β ( Figure 5A ), an indication of GSK3β activation. In contrast, low-dose LPS failed to induce Tyr216 in either IRAK-1-deficient or Tollip-deficient macrophages ( Figure 5A ).
To confirm the role of GSK3β in low-dose LPS-mediated suppression of cholesterol exporters, we measured the expression levels of Sr-b1, Abca1/Abg1 in WT and GSK3βdeficient murine embryonic fibroblasts. As shown in Figure  5B , similar to the effects seen in macrophages, low-dose LPS suppressed the expression of these exporters in WT murine embryonic fibroblast cells. In contrast, LPS failed to suppress these exporters in GSK3β-deficient murine embryonic fibroblast cells.
Severe Suppression of Cholesterol Efflux in IRAK-M-Deficient Cells
Given the fact that IRAK-M counteracts the function of IRAK-1, 33 we tested the expression of cholesterol exporters and cholesterol efflux in IRAK-M-deficient macrophages. As shown in Figure 6A , the basal efflux efficiency to either ApoA-1 or HDL was significantly lower in IRAK-M-deficient macrophages, as compared with that in WT macrophages. Low-dose LPS further decreased cholesterol efflux in IRAK-M-deficient macrophages.
We then examined the levels of SR-B1, ABCG1, and ABCA1 in WT and IRAK-M-deficient macrophages. We observed that, as compared with the WT cells, the resting protein levels of SR-B1 and ABCG1 were significantly lower in IRAK-Mdeficient cells ( Figure 6B ). Low-dose LPS further decreased the levels of SR-B1 and ABCG1. Similar effects were seen at the message level through RT-PCR analyses ( Figure 6C ). The levels of ABCA1, however, were not significantly altered among WT and IRAK-M-deficient macrophages, indicating that these exporter genes may be differentially regulated by IRAK-1 and IRAK-M. Interleukin-1 receptor-associated kinase 1 (IRAK-1) and Tollip are involved in the low-dose lipopolysaccharide (LPS)-mediated suppression of retinoic acid receptor-α (RARα). The bone-marrow-derived macrophages (BMDMs) derived from WT, IRAK-1-deficient, and Tollip-deficient mice were treated with low-dose LPS (50 pg/mL) for the indicated times followed by nuclear protein extraction. Equal protein aliquots (50 μg) were processed for immunoblotting with (A) anti-RARα and liver X receptor (LXR)-α, and (B) anti-steroid receptor coactivator 3 (SRC3) antibodies. The same blots were reprobed with anti-LaminB to control for protein loading. C, WT, IRAK-1-deficient, and Tollip-deficient BMDMs were either untreated or treated with low-dose LPS (50 pg/mL) for 2 hours and subjected to a chromatin immunoprecipitation (ChIP) assay using the specified antibodies. The primers spanning the PPRE and DR4 region on the Srb1, Abca1, and Abcg1 promoters were used in the ChIP assays. Data are representative of 3 independent experiments. The band intensities were quantified using the Fujifilm Multi Gauge software, and the fold suppression is depicted after normalization against input levels.
To further determine the molecular mechanism, we measured the levels of RARα in WT and IRAK-M-deficient macrophages treated with low-dose LPS. As shown in Figure 6D , basal levels of RARα were significantly lower in IRAK-M-deficient macrophages and were further decreased upon low-dose LPS challenge. We also performed chromatin immunoprecipitation analyses to determine the recruitment of RARα to the SR-B1 promoter. As shown in Figure 6E , the recruitments of RARα to SR-B1 promoter were significantly reduced in IRAK-M-deficient macrophages. As RARα often form dimers with other nuclear receptors such as PPARα, and that PPARα is also implicated in the transcription of SR-B1, [34] [35] [36] we further examined the recruitment of PPARα to the promoter of Sr-b1 in WT and IRAK-M-deficient cells.
Opposing Effects of IRAK-1/Tollip and IRAK-M in the Foam Cell Formation Mediated by Low-Dose LPS
To determine the functional consequence of our mechanistic observation, we performed foam cell formation assay using primary macrophages from WT, IRAK-1-deficient, Tollipdeficient, and IRAK-M-deficient mice. As shown in Figure 7 , low-dose LPS significantly increased foam cell formation in WT macrophages. In contrast, the effect of low-dose LPS was ablated in either IRAK-1-deficient or Tollip-deficient macrophages. However, IRAK-M-deficient macrophages exhibited elevated foam cell formation, even without the treatment of LPS as compared with WT cells. Low-dose LPS further elevated foam cell formation in IRAK-M-deficient macrophages.
Taken together, our data reveal a novel mechanism responsible for the suppression of cholesterol export in macrophages by subclinical dose of endotoxin ( Figure 8 ).
Discussion
Our current report reveals not only the suppressive effects of low-dose LPS on cholesterol efflux in macrophages, but also the underlying molecular mechanisms. First, we demonstrated that low-dose LPS reduces the expression of key cholesterol exporters, including SR-B1, ABCA1, and ABCG1 in macrophages, through an IRAK-1-dependent and Tollipdependent mechanism. Second, IRAK-1 and Tollip suppress their expression through GSK3β-mediated inhibition of nuclear receptors, such as RARα. Third, IRAK-M serves as an antagonist for IRAK-1 and exerts opposing effects on the modulation of SR-B1 and cholesterol export in macrophages (Figure 7) .
Our data provide a mechanism explaining the link between subclinical low-dose endotoxemia and atherosclerosis. Recent human and animal studies indicate that slightly elevated levels of circulating endotoxin are closely associated with risks of atherosclerosis. 7, 9, [37] [38] [39] [40] [41] To this regard, it is worth to note that macrophages can be programmed to opposing phenotypes by low-versus high-dose LPS. 42, 43 High-dose endotoxin can induce both proinflammatory mediators and compensatory antiinflammatory mediators. 44 As a consequence, a transient and resolving inflammatory response may ensue after an acute high-dose LPS challenge. In contrast, low-dose endotoxin preferentially skews toward mild expression of proinflammatory mediators that may lead to low-grade, yet nonresolving inflammatory complications. 45 In addition to the chronic skewing of proinflammatory environment, we, herein, demonstrate that subclinical low-dose endotoxin also potently suppresses the expression of key cholesterol exporters, including SR-B1 and ABCA1/ABCG1, and, consequently, reduces cholesterol efflux from macrophages. Our functional study further demonstrates increased foam cell formation in macrophages treated with low-dose LPS. Consistent with our observation, a previous study demonstrates that double deletion of SR-B1 Figure 5 . Low-dose lipopolysaccharide (LPS) activates glycogen synthase kinase 3β (GSK3β) in interleukin-1 receptor-associated kinase 1 (IRAK-1)-dependent and Tollip-dependent manner. A, Wild-type (WT), IRAK-1-deficient, and Tollip-deficient bone-marrow-derived macrophage (BMDM) cells were treated with low-dose LPS (50 pg/mL) for the indicated times. Whole cell lysates (75 μg) were subjected to immunoblot analyses with total GSK3β, pGSK3β-Ser9, and pGSK3β-Tyr216-specific antibodies. The same blots were reprobed with anti-ACTIN to confirm equal total protein levels. The data are representative of at least 3 independent experiments. The band intensities were quantified using the Fujifilm Multi Gauge software, and the relative levels were depicted after normalization against β-actin levels. * indicates P<0.05 compared with the untreated control samples. B, GSK3β +/+ and GSK3β −/− murine embryonic fibroblasts (MEFs) were left untreated or treated with low-dose LPS (50 pg/mL) for 18 hours, and total RNA was isolated. Expression levels of Srb-1, Abca1, and Abcg1 messages were evaluated by quantitative RT-PCR, and Gapdh was used for normalization. Data are expressed as means±SD of 3 independent experiments. and ABCA1 further compromises cholesterol efflux in macrophages, significantly induces foam cell formation, and dramatically exacerbates the pathogenesis of atherosclerotic plaques. 46 This is in contrast to the effects of high-dose LPS (>100 ng/mL) that may either suppress or activate ABCA1 expression depending upon different experimental settings. 24, 47 Likewise, high levels of lipids and lipoproteins in humans can also induce the expression of both proinflammatory mediators, as well as antiinflammatory and lipid-lowering molecules, such as ABCA1. 48 This conflicting paradigm developed by the host may be a controlled compensatory response to fine-tune the proinflammatory and antiinflammatory balance. 42, 49 Our study reveals that subclinical low-dose LPS may pose a much severe danger by potently suppressing the antiinflammatory cholesterol exporters from macrophages, thus depriving the compensatory mechanism to maintain proper homeostasis and resolve inflammation.
Our report underscores the significant role that IRAK-1 and Tollip plays in mediating the effect of low-dose LPS. Although both molecules were previously shown to physically associate with LPS receptor toll-like receptor-4, their functional roles are largely not well defined. IRAK-1 seems to be redundant with either IRAK-2 or IRAK-4, when cells are challenged with a high-dose LPS or interleukin-1β. 50, 51 The effect of Tollip is also minimal in cells treated with highdose LPS. 26 Instead, our data clearly indicate that IRAK-1 and Tollip are essential for suppressing cholesterol efflux from macrophages treated with subclinical low-dose LPS. It is likely that additional regulatory mechanisms, other than IRAK-1 and Tollip, may be triggered in cells treated with high-dose LPS. These additional mechanisms may be involved in the compensatory modulation of macrophage activation and homeostasis. (BMDMs) . A, Wild-type (WT) and IRAK-M −/− BMDMs were radiolabeled with [ 3 H] cholesterol in cell culture medium for 18 hours, and then treated with low-dose LPS in the presence of apolipoprotinA-1 (apoA-1; 10 μg/mL) or HDL (50 μg protein/mL). Cellular cholesterol efflux was analyzed by liquid scintillation counting assays. Efflux rates were calculated as described in the online-only Data Supplement Methods, and the results are expressed as means±standard deviations from 3 independent experiments, each performed in triplicate. * indicates P<0.05 compared with the untreated control samples. + P<0.05 compared between WT and IRAK-M-deficient cells. B, WT and IRAK-M -/-BMDMs were treated with 50 pg/mL LPS for the indicated time points followed by whole-cell protein extraction. The samples (70 μg) were resolved by SDS-PAGE followed by immunoblotting with anti-ABCG1 and scavenger receptor B1 (SR-B1) antibodies. β-actin was probed as loading controls. C, The BMDMs derived from WT and IRAK-M −/− mice were treated with low-dose LPS for 18 hours followed by total RNA extraction. The resulting cDNAs were used to detect Srb-1 and Abcg1 transcript levels by RT-PCR and standardized against Gapdh levels. Each experiment was performed in triplicate. * indicates P<0.05 compared with the untreated control samples. + P<0.05 compared between WT and IRAK-M-deficient cells. D, The BMDMs derived from WT and IRAK-M-deficient mice were treated with low-dose LPS (50 pg/mL) for the indicated times followed by nuclear protein extraction. Equal protein aliquots (50 μg) were processed for immunoblotting with anti-retinoic acid receptor-α (RARα) antibodies. The same blots were reprobed with anti-LaminB antibodies to control for protein loading. The band intensities were quantified using the Fujifilm Multi Gauge software, and the relative levels were depicted after normalization against Lamin-B levels. * indicates P<0.05 compared with the untreated control samples. + P<0.05 compared between WT and IRAK-M-deficient cells. E, WT and IRAK-M-deficient BMDMs were either untreated or treated with low-dose LPS (50 pg/mL) for 2 hours and subjected to a chromatin immunoprecipitation (ChIP) assay. The primers spanning the PPAR-response element region on the Sr-b1 promoter, and the specified antibodies were used in the ChIP assays. Data are representative of 3 independent experiments.
Our finding reveals that IRAK-1 and Tollip modulate the effect of low-dose LPS through GSK3β. This is consistent with previous report that GSK3β is closely associated with the proinflammatory skewing of macrophages in vitro and in vivo. 32, 52 GSK3β is also shown to contribute to the phosphorylation and proteasome-mediated degradation of PPARα and RARα. 31, 53 This is in agreement with our finding that low-dose LPS suppresses RARα through IRAK-1/Tollip-mediated activation of GSK3β. Our data indicate that IRAK-1 and Tollip sit upstream of GSK3β and are responsible for the tyrosine phosphorylation of GSK3β induced by low-dose LPS. However, it is not clear whether IRAK-1 may either directly or indirectly contribute to GSK3β phosphorylation. Given the fact that IRAK-1 is a putative serine/threonine kinase, it is likely that IRAK-1 may indirectly lead to GSK3β Tyr216 phosphorylation through another unknown intermediate kinase.
Future works are clearly warranted to clarify this important connection.
IRAK-M is known as a general inhibitor of IRAK-1 function. 33, 54 Extending upon these observations, our data reveal that IRAK-M counteracts IRAK-1 and selectively sustains the levels and activities of RARα, as well as the expression of cholesterol exporters SR-B1, ABCA1/ABCG1. Based on our mechanistic findings, it is likely to posit that IRAK-M is beneficial in attenuating the pathogenesis of atherosclerosis and foam cell formation. Indeed, our preliminary data indicate that ApoE -/-/IRAK-M -/mice develop much severe atherosclerosis as compared with ApoE -/mice, when fed with a high-fat diet. However, we previously published that ApoE -/-/IRAK-1 -/mice have attenuated development of atherosclerosis as compared with ApoE -/mice. 55 This study is limited to the preconditioning of macrophages by low-dose LPS, and the modulation of signaling pathways responsible for the reduced expression of cholesterol transporters in naive macrophages. To our knowledge, this is the first attempt to reveal the intracellular signaling network responsible for the novel activation of GSK3β, and suppression of nuclear receptors involved in the expression of ABCA1, ABCG1, and SR-B1 by low-dose LPS. The dynamic competition among IRAK-1 and IRAK-M plays a key role in mediating the effect of low-dose LPS. It is worth noting that there may be differences involved in the regulation of these transporters in macrophages by low-dose LPS. As shown in our data, although IRAK-1 and Tollip are involved in the suppression of ABCA1, ABCG1, and SR-B1, IRAK-M is selectively involved in the suppression of SR-B1 and ABCG1. Other unknown intracellular molecules may also be involved in the differential regulation of these transporters.
In addition to cholesterol transport, low-dose LPS may also affect the expression of additional modulators that can potentially affect cholesterol metabolism and transport. Although not a focus of this work, we performed limited study and examined the modulation of ApoE expression by low-and highdose LPS. Although high-dose LPS (100 ng/mL) suppresses the expression of ApoE, low-dose LPS fails to affect ApoE expression ( Figure I in the online-only Data Supplement). Future detailed biochemical analyses are required to further dissect the molecular networks involved in the unique regulation of these genes involved in cholesterol metabolism and transport in macrophages.
It is important to note that macrophages can not only be preconditioned by low-dose LPS, but may also be preprogrammed by other distinct proinflammatory stimulants and mediators. For example, macrophages can be preprogrammed by interferon-γ, leptin, and interlaukin-4, and adopt either a proinflammatory or antiinflammatory state. [56] [57] [58] It remains to be tested whether cholesterol, oxidized low-density-lipoprotein, or other lipid mediators may also capable of preconditioning macrophages, and affect their subsequent responses to inflammatory signals, such as LPS. Conceivably, macrophages are dynamically modulated depending upon the timing and threshold of simultaneous or sequential challenges of multiple stimulants. The modulation of molecules involved in the toll-like receptor-4 pathway has not been carefully studied and should be systematically examined in the future both in vitro and in vivo. In this regard, we have attempted a systems biology approach employing computational tools to define the dynamic priming and tolerance of macrophages, as well as skewing of T-helper cells to distinct states. 59, 60 Future singlecell analyses with detailed live-cell kinetics are required to further define this complex, yet highly important dynamics in macrophages.
Our in vitro mechanistic data are consistent with in vivo studies published by our group and others. IRAK-1 or IRAK-4 deletion in ApoE-deficient background led to reduced atherosclerosis in mice. 55, 61 GSK3β activation was recently shown to be critically involved in the pathogenesis of atherosclerosis. 62 Known GSK3β inhibitors and emerging small-compound inhibitors for IRAK-1 may serve as attractive candidates for the development of effective drugs for the treatment of atherosclerosis. Future in vivo studies in animals and humans are warranted to define the involvement of Tollip and IRAK-M during the pathogenesis of atherosclerosis associated with low-dose endotoxemia and low-grade inflammation.
Taken together, our signaling study uncovers a dynamic and competing intracellular circuit, involved in modulating cholesterol efflux in macrophages. Given its dynamic and competing nature, we postulate that host macrophages may either undergo proper cholesterol export or be programmed into nonresolving foam cells, when challenged with varying dosages of LPS or other stimulants. Our signaling study sets the stage for future functional works in defining the dynamic modulation of cholesterol efflux from macrophages, and reveals potential molecular targets for the effective intervention of atherosclerosis.
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This study was supported by funds from the National Institute of Health NIH R01 HL115835, American Heart Association, and Virginia Tech to L.L. Figure 8 . An illustration of potential mechanisms responsible for the suppression of cholesterol exporters in macrophages by low-dose lipopolysaccharide (LPS). Low-dose LPS reduces the expression of scavenger receptor B1 (SR-B1), ABCA1/ABCG1 through reduction of retinoic acid receptor-α (RARα) mediated by interleukin-1 receptor-associated kinase 1 (IRAK-1)/Tollipinduced activation of glycogen synthase kinase 3β (GSK3β). IRAK-M, however, counteracts such effect.
